Mucolytic pharmaceutical composition |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
IPC classes for russian patent Mucolytic pharmaceutical composition (RU 2286143):
 3-apatitenepheline or pyrrolidine as antagonists tachykinin, methods for their preparation, intermediate compounds, pharmaceutical composition and method of treatment / 2158264
The invention relates to therapeutic tools, specifically setidentityproviderid N-substituted nitrogenous heterocyclic compounds and methods of producing such compounds, intermediate products used in obtaining, compositions containing such compounds and the use of such heterocycles
 The polymers of alkylarylsulfonates with antioxidant properties / 2147235
The invention relates to the field of medicine and for the application of polymer alkylarylsulfonates for effective inhibition of oxidant in chemical or biological system, as well as medications, including those polymeric compounds
Method for preparing enterosorbent / 2285542
Method involves mixing polyphepan with a binding agent, drying a mixture and tabletting. Lactose is used as a binding, slipping and lubricating agent. After mixing components the prepared mixture is granulated and wetted granules are fed for drying up to residual moisture value 8%, not above. After drying termination granules are milled to particles size less 3.0 mm and then crushed granules are fed for tabletting and tablets with weight 0.5 g (± 0.025 g) are made of the following composition, g: polyphepan (as measure for dry matter), 0.35-0.40, and lactose, the balance. Invention provides retaining the sorption activity of polyphepan and to simplify the process.
 Pharmaceutical dosed formulation for delivery through mucosa / 2285520
Invention relates to a pharmaceutical tablet comprising a medicinal agent taken in the therapeutically and/or prophylactically effective amount. Tablet has a core disintegrated in mouth cavity and an envelope made of an adjusting excipient wherein envelope comprises hellanic gum. Practically all medicinal agent is comprised in the core and doesn't mixed with hellanic gum and wherein a medicinal agent represents compound of the formula (I)
 Method and apparatus for manufacture of small-sized, thin sheet articles from active film component / 2285518
Method involves manufacturing small-sized, thin, sheet articles from active film component 2, wherein active film component is obtained by forming of film material on substrate or by applying onto substrate; storing it on bobbin in conjunction with substrate or without it; removing film component from bobbin and cutting it. Active film component 2 is automatically removed from bobbin, separated from substrate, in case it is available, and fed in stretched state to zone of cutting into strips, where it is initially cut into narrow strips 7 of desired width, then said strips are connected in feeding direction and fed in such a state by means of additional feeding device 10 to cross cutting device 11 for cutting group of elongated strips 7 in predetermined intervals.
Stable peroral solid composition of medicinal preparation / 2284819
The present innovation deals with stable peroral solid composition of ramosetron or its pharmaceutically acceptable salt. The composition includes one or several components chosen out of the groups including aliphatic carboxylic acid or its ester, hydroxycarboxylic acid or its ester, acidic amino acid, enolic acid, aromatic carboxylic compound or its ester and high-molecular substance that contains carboxylic group. Such an innovation refers to the method for stabilizing ramosetron composition. The suggested innovation provides stability of ramosetron composition under conditions of increased temperature and humidity, especially at low content of active component.
Anthacidal and aperient tablet / 2284189
Claimed tablet for peroral administration contains particles of magnesium oxide as active ingredient, wherein 1) magnesium oxide particles containing in tablet, have average secondary size measured by laser IR-scattering of 0.5-10 mum; 2) tablet contains 99 mass % or more of magnesium oxide particles: 3) tablet is not blacked and essentially has no spots formed in pelletization process; and 4) tablet disintegration time is 10 s or less.
 Porous carrier application / 2283140
Device has porous ceramic carrier layers and transverse bracing members, connected carcass having pores most of which have size from 20 to 1000 mcm and possessing density of 40% with respect to the theoretical one. Volume of the pores is optionally filled with a drug known to have controllable release rate from the filler.
 Composition with hepatoprotective and metabolism normalizing activity / 2283114
Claimed composition contains both plant and animal origin phospholipid, essential amino acid such as methionine and threonine, and filler at total phospholipid and amino acid content of 15-80 % in mass ratio of 2:1.
Anti-inflammatory medicinal agent / 2283112
Invention proposes a medicinal agent for oral administration possessing an anti-inflammatory effect. Medicinal agent is made as a solid dosed formulation for oral administration that comprises meloxicam as an active substance, stearic acid or stearate as a slipping substance, maltodextrin as a binding agent, croscarmellose sodium salt as a disintegrating agent and dextrin as a filling agent taken in the definite ratio of components. Invention provides enhancing the biological availability of agent and improving its consumption properties. Invention can be used in the development of a medicinal agent made as a solid dosed formulation for oral administration possessing an anti-inflammatory effect.
 Hydrophilic nateglinide-containing pharmaceutical preparation / 2283104
Invention proposes a hydrophilic pharmaceutical composition with hypoglycemic effect comprising nateglinide crystals of B-type as an active component. The composition has edge angle to water surface 111 degrees or less. This edge angle is created by addition at least one hydrophilic substance to the composition chosen from groups comprising of hydrophilic polymers, surfactants, sugars and sugar-alcohols. Invention provides easy method for preparing the composition, its high solubility and rather rapid release of nateglinide.
Dry granulated azithromicine compositions / 2283092
Claimed composition contains particles of azithromicine non-dehydrated form obtained by dry granulation method and optionally one or more pharmaceutically acceptable excipient. Pharmaceutical composition preferably represents tablet containing approximately 40-85 mass % non-dehydrated azithromicine. More preferably pharmaceutical composition contains non-dehydrated azithromicine selected from F, G, J, M forms or mixtures thereof. Most preferably pharmaceutical composition contains azithromicine (A) in dose of 250 mgA, 500 mgA, 600 mgA, or 1000 mgA. Also disclosed is azithromicine particles obtained by dry granulation method that containing azithromicine form selected from F, G, J, M forms and mixtures of non-dehydrated forms, and at least one pharmaceutically acceptable excipient.
Method for indirect regional lymphotropic chemotherapy in infiltrative, destructive and drug-resistant pulmonary tuberculosis / 2281093
Method involves firstly the achievement of lymphotropicity of three chemopreparations by addition of 5% glucose and aloe to solutions of these chemopreparations. Then the conduction paravertebral anesthesia is carried out at the level and at side of administration of preparations. Then three chemopreparations are administrated separately in different intercostals sites, 1-3 times per a week, course of 4-12 injections by subcutaneous paravertebral route, parasternal route in I-X intercostals - in projection of regional lymphatic collectors. Method allows reducing the duration of intensive phase in tuberculosis treatment up to 1-3-6 months, to prevent the development of drug-resistant tuberculosis and adverse effects of chemopreparations and to relieve the residual changes of tuberculosis. Invention can be used in treatment of infiltrative, destructive and drug-resistant pulmonary tuberculosis.
Method for treatment of malignant tumor / 2272647
Invention relates to a method for treatment of malignant tumors. Method involves chemotherapy and hormonal therapy. Insulin of short action is administrated by subcutaneous injection in the dose 8-10 U as a hormone. In appearance of hypoglycemia symptoms chemopreparations are administrated in 200-250 ml of 40% glucose solution. Administration is carried out once time for 3-6 weeks by the known schedule. Method provides enhancing antitumor effect of chemopreparations due to reducing delivery of glucose into malignant cell, its energy deficiency and reducing adaptation ability to chemotherapy.
Method for intermittent lymphotropic (subxyphoidal) therapy in patients after reconstructive esophageal operations / 2265449
The present innovation deals with treating patients in early post-operational period after interferences in mediastinal and esophageal organs. One should conduct the course of subxyphoidal bolus injection of lymph-stimulating mixture containing 64 U lidase diluted in 1 ml 5%-glucose, 25 mg suspension of hydrocortisone followed by slow drop-by-drop injection of 500 mg metrogil during the first 3 d of post-operational period. The innovation provides high concentration of curative preparations in operation region at decreasing their dosages, decreased toxic effects and risk of purulent-inflammatory complications due to stimulating drainage-detoxication function of lymph system.
 Method for experimental modeling urinary calculosis / 2248045
The present innovation deals with modeling urinary calculosis in rats due to injecting intraperitoneally 60%-glucose solution at 1 ml/100 g animal body weight twice daily for 2 mo. The method is very simple and enables to achieve lithogenesis in 25% experimental animals.
Method for lymphostimulation and immunomodulation in cerebrospinal sclerosis / 2246942
Method involves intravenous administration of autolymphocytes treated with an immunomodulating agent by extracorporal method using cycloferon (250 mg) as an immunomodulating agent. Simultaneously, the following medicinal mixture comprising lidocaine, 100 mg; lidazum, 32 U; dexamethasone, 4 mg; leukinferon, 10 000 U; 40% glucose solution, 4 ml is administrated into interspinal ligaments of spinal column at levels corresponding to thoracal and lumbar enlargements of the spinal cord. The procedure is repeated three times with interval for 48-72 h. Method provides enhancing the effectiveness of lymphostimulation and immunomodulation in cerebrospinal sclerosis. Invention can be used for lymphostimulation and immunomodulation in cerebrospinal sclerosis.
Antitumor agent / 2228757
The invention relates to the field of medicine and for the creation of anti-cancer drugs
 Material for thermal and time indicators sterilization / 2214838
The invention relates to medicine, in particular to the means of control of thermal processes, and can be used to control the modes of the air sterilization of medical products
 The method of obtaining rehydration means "rehydration navigation" / 2195938
The invention relates to veterinary science and medicine
|
FIELD: pharmaceutical industry, in particular mucolytic pharmaceutical agent. SUBSTANCE: claimed composition contains therapeutically effective amount of bromohexin as active ingredient and sugar, starch and stearinic acid salt as target additives. Pharmaceutical composition is provided in form of tablets. EFFECT: composition with improved physical and pharmaceutical properties, such as dissolving and active ingredient releasing. 8 cl, 2 tbl, 4 ex
The invention relates to medicine, specifically to medication to help remove sputum from pulmonary tract. For a long time the main drugs used for this purpose were expectorants the action of which is largely due to the stimulation of the receptors of the mucous membranes of the bronchial paths and mechanical strengthening of the promotion of sputum. Recently, there are new opportunities to improve the "drain" function bronchial pathways by pharmacological means. The number of new drugs allows you to change the rheological properties of sputum and its adhesive performance, as well as to facilitate the removal of mucus physiological way. Currently, the drugs used for the removal of phlegm, divided into two main groups: - stimulate extract (secretomotor); - mucolytic (bronhosekretoliticheskie). The drug Bromhexine has mucolytic action. Now it is proved that the effect of Bromhexine due to its specific ability to stimulate the production of endogenous surfactant - surfactant of lipids-protein-mukopolisaharidnyh nature, synthesized in the alveolar cells (Mashkovsky PPM Medicines, M.: OOO "New wave", 2002, vol. 1, p.346). Violation bio is Intesa surfactant is observed at various bronchopulmonary diseases and the use of stimulant education surfactant is regarded as one of the most important pathogenetic links pharmacologic treatment of these diseases. It was also established that deficiency of lung surfactant is observed in the syndrome of respiratory disorders (respiratory distress syndrome) in infants. In accordance with the mechanism of their action Bromhexine is used as an expectorant in acute and chronic bronchitis different etiology, infectious-allergic form of asthma, pulmonary tuberculosis, acute and chronic pneumonia. The drug can be used for the renovation of the bronchial tree in the preoperative period, and to prevent congestion in the bronchi thick viscous sputum after the operation. Bromhexine use in medical practice, primarily in the form of tablets and syrups, although from the literature known solid dosage forms of Bromhexine in the form of powders, tablets, coated tablets, effervescent tablets, capsules, etc. (UK Patent No. 1464082, 1977, application WO 92/01449, 1992, U.S. patent No. 4229477, 1980, RF patent №2189228, 2002). In the United Kingdom patent No. 968254, 1964, first described Bromhexine, which, along with a group of other new digalog-Amin-benzylamino has secretolytic activity of a single dose of 0.5-10 mg In the United Kingdom patent 1464082, 1977, describes pharmaceutical preparations containing benzylamine, including Bromhexine. Every single Lek is stunna dose contains 30-100 mg of active substance. These doses substances possess antiulcer activity. Daily dose of the drug antiulcer action is 90-400 mg. Example 1 shows the composition of the tablets, mg (parts by weight):
The total weight of the tablet 240 mg Get pills, mixing Bromhexine with calcium phosphate, Aerosil and corn starch, granularit with 10%solution of polyvinylpyrrolidone in ethanol containing pre-dissolved maleic acid, sceneroot through a sieve with the hole diameter of 1.5 mm, dried at 45°and again sceneroot 1.5 mm, the Obtained granulate is mixed with potato starch and magnesium stearate and pressed into tablets. The disadvantage of this pharmaceutical composition is produces with the rod and rather laborious way of its receipt. In the application WO 92/01449, 1992 (parts by weight) described psychoactive drug, including Bromhexine or its salts. The following formulations of tablets, mg (parts by weight): Part (I):
Mannitol granularit add to dry granules remaining ingredients and then tabletirujut. Composition (2):
The medicinal substance, starch and lactose heliroute, granularit, mixed with talc and stearic acid and tabletirujut. The weight of the tablets is not specified. In U.S. patent 4229477, 1980, describes a pharmaceutical composition for the treatment of diabetic neuropathies, containing as active substance brompheniramine chloride and excipients. Example 1 shows the composition of the pills salt Bromhexine mg (parts by weight):
The total weight of the tablet 240 mg of the Active agent is mixed with lactose and corn starch, homogenized with 10%aqueous solution of gelatin, granularit, dried, again granularit; the granules are mixed with magnesium stearate and pressed into a tablet; the resulting core is covered with a mixture of sugar and talc. In the above analogues use other, higher number of Bromhexine. Recently in the application of Bromhexine on its main purpose, namely as a mucolytic agents, in clinical practice it is customary to use the tablet for adults containing 0.008 g (8 mg) Bromhexine, and for children - - containing 0.004 g (4 mg) of Bromhexine. Accordingly, when the treatment with Bromhexine appoint either of the above quantity, or multiples of them (Mashkovsky PPM, ibid.). However, information about the composition and the number of target components in open publications are practically absent. The objective of the present invention is under the ora optimal combination of excipients to create a mucolytic pharmaceutical compositions on the basis of Bromhexine, made in the form of tablets, which meets the requirements of current Russian regulatory documents and expands the Arsenal of currently available medicines. The technical result that is being achieved in the implementation of the present invention, is that the proposed mucolytic pharmaceutical compositions on the basis of Bromhexine raspadaemost tablets does not exceed 15 minutes and when dissolved in 45 minutes is not less than 75% of active substance, which ensures its high bioavailability. The shelf life of the tablets is not less than 2 years (see table 2). This object is achieved mucolytic pharmaceutical composition comprising a therapeutically effective amount of Bromhexine and targeted supplements, which use sugar, starch, and salt of stearic acid in the following ratio of components, parts by weight/1 parts by weight of active ingredient:
As sugar use sugar and/or milk sugar. The ratio of sugar÷milk sugar varies in the interval 0÷3,0, mainly 0,4÷2,5. As starch is suitable potato and/or corn starch and/or glycolate, sodium starch. As a salt of stearic acid using magnesium or calcium salts. The proposed ratio of the active substance and the target additives found experimentally and is optimal, provide mucolytic pharmaceutical compositions made in the form of a solid dosage form, the satisfaction of all regulatory requirements, and the shelf life of Bromhexine tablets is not less than 2 years (see table 2). Going beyond the lower limit of the ratios of the basic substance and the target additives leads to deterioration of the technological parameters of the process of obtaining the medicinal form of Bromhexine, and the increase of target components is impractical, because it reduces the quality of the individual indicators pharmacopoeial product. Dosage form Bromhexine is made in solid dosage form, mainly in the form of tablets. Each tablet contains 0.004 g ± 10% or 0.008 g ± 10% of Bromhexine. Tablet Bromhexine get known method of wet granulation. The obtained tablets meet all regulatory requirements and have a shelf life of at least 2 years (see table 2). The following examples illustrate the invention. Example 1. (The ratio of components see table 1). A mixture of 4.0 g of powder of Bromhexine hydrochloride, 4.7 grams of potato KRA is small, by 60.0 g of lactose and 30.0 g of powdered sugar moistened with a 3%aqueous solution of starch paste (from 0.2 g of starch, mix until smooth and pass through a granulator. The granulate is dried at 30 to 45°to a residual moisture of 3-5%. The dried granules are passed through a granulator and optivault a mixture of 0.4 g of magnesium stearate and 0.1 g glycolate, sodium starch (primogel) and tabletirujut on the press. Get 940 tablets with an average weight of each tablet 0,100 g and an average content in one tablet 0,0040 g of Bromhexine. The resulting tablets have the following quality indicators: raspadaemost 3 min; dissolution for 45 min released 100,0% active ingredient; a shelf life of not less than 2 years. Thus, the obtained tablets comply with all the requirements of regulatory documents (see table 2). Example 2. (The ratio of components see table 1). Obtaining tablets of Bromhexine carried out as in example 1 on the basis of 8.0 g of Bromhexine, 4.0 g of corn starch to 57.1 g of powdered sugar, 142,9 g of milk sugar and 2.4 g of calcium stearate. Get 980 tablets with an average weight of one tablet of € 0.195 g, and the average content in one tablet 0,0081 g of Bromhexine. The obtained tablets meet all regulatory requirements and have a shelf life of 2 years (see table 2). Example 3. (The ratio of components see table 1). Obtaining tablets bromine who exina carried out as in example 1 on the basis of 4.0 g of Bromhexine hydrochloride, 7,8 g of potato starch, 42.9 g of sugar, 17.1 g of lactose, 0.2 g primogel and 0.8 g of magnesium stearate. Get 780 tablets with an average weight 0,093 g and an average content in one tablet 0,0042 g of Bromhexine. The resulting tablets have a shelf life of 2 years and meet all regulatory requirements (see table 2). Example 4. (The ratio of components see table 1). Obtaining tablets of Bromhexine carried out as in example 1 on the basis of 8.0 g of Bromhexine hydrochloride, 0.8 g of potato starch, by 60.0 g of lactose and 0.8 g of calcium stearate. Get 770 tablets with an average weight 0,090 g and an average content in one tablet 0,0085 g of Bromhexine. The resulting tablets have a shelf life of 2 years and meet all regulatory requirements (see table 2).
1. Mucolytic pharmaceutical composition comprising as active substance Bromhexine and target additives, characterized in that it contains a therapeutically effective amount of Bromhexine, as well as special additives it contains sugar, starch and salt of stearic acid in the following ratio of components, parts by weight/1 parts by weight of active ingredient:
2. The pharmaceutical composition according to claim 1, characterized in that as the sugar it contains mainly lactose and/or powdered sugar. 3. The pharmaceutical composition according to claim 2, characterized in that the ratio of sugar ÷ milk sugar is in the range of 0÷3,0 mainly 0,4÷2,5. 4. The pharmaceutical composition according to claim 1, characterized in that the starch it contains potato and/or corn starch and/or glycolate, sodium starch. 5. The pharmaceutical composition according to claim 1, characterized in that the quality salt of stearic acid it contains magnesium and/or calcium salts. 6. The pharmaceutical composition according to any one of claims 1 to 5, characterized in that it is made in the form of solid dosage forms. 7. The pharmaceutical composition according to claim 6, characterized in that it is made in the form of tablets. 8. The pharmaceutical composition according to claim 1, wherein the tablet contains Bromhexine 0.004 g ± 10% or 0.008 g ± 10% active ingredient.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
